Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Food Effect on Fuzuloparib PK in Healthy Chinese Subjects
NCT05440006Phase 1Completed
- Sponsor
- Hengrui
- Start
- Jul 2022
- Primary completion
- Jul 2022
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, open-label trial of fluzoparib in solid tumor (2 arms), sponsored by Hengrui. Primary endpoints: Maximum Plasma Concentration, Area under the plasma concentration versus time curve from time 0 to last time of measurable concentration and 1 more. Started Jul 2022; status: completed.
02
Drugs
fluzoparib
03
Conditions
solid tumor
Beyond the preview
Go deeper on NCT05440006.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05440006.